Jan 14, 2022 / 08:00AM GMT
Operator
Hello, and welcome to the Donesta top line efficacy results Phase III. My name is Courtney, and I'll be your coordinator for today's event. Please note that this call is being recorded.
(Operator Instructions)
And I will now hand you over to your host, Benoit Mathieu, Group Investor Relations Manager, to begin today's conference. Thank you.
Benoit Mathieu - Mithra Pharmaceuticals SA - Group IR Manager
Good morning, ladies and gentlemen. Welcome to all of you. And as you have seen in our press release this morning, we have decided to organize this webcast in order to present in more details to Donesta top line efficacy results. My name is Benoit Mathieu, Investor Relations Officer, and I'm joining the room by our CEO, Leon Van Rompay; Graham Dixon, our Chief Scientific Officer; and Jean-Michel Foidart, our Chief Business Officer.
This webcast is recorded and will be accessible later today on Mithra's website. I would like to remind you that this webcast is covered by the disclaimer on Slide 2 of this presentation. The format of today
Mithra Pharmaceuticals SA to Discuss Donesta Top-Line Results Call Transcript
Jan 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers